Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Granted 60 Days To Produce Audit Documents in DOJ Investigation

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Maryland District Court Judge Peter Messitte has granted a sixty day "abeyance" from a motion filed by the U.S. Department of Justice against Ranbaxy on charges of concealing information regarding one of its manufacturing plants in India
Advertisement

Related Content

Ranbaxy Internal Audit Disclosure Highlights U.S. FDA Policy Exceptions
Ranbaxy Internal Audit Disclosure Highlights U.S. FDA Policy Exceptions
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
Advertisement
UsernamePublicRestriction

Register

SC069189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel